Application of Ex Vivo Normothermic Machine Perfusion in Deceased Donors With Acute Kidney Injury With Successful Renal Transplantation: A Preliminary Experience.

Ex vivo normothermic machine perfusion (NMP) has improved organ preservation and viability assessment among heart, liver, and lung transplantation. However, literature regarding the application of NMP in human clinical kidney transplantation remains limited. Numerous kidneys, especially from donors with stage 3 acute kidney injury (AKI), are not utilized concerning the high rate of delayed graft function (DGF) and primary nonfunction. The present study investigated the impact of NMP (135-150 min) on short-term outcomes after kidney transplantation from deceased donors with AKI. Methods: Graft outcomes of NMP kidneys were compared with contralateral kidneys stored in static cold storage (SCS) from the same donor with AKI during December 2019-June 2021. The study's primary aim is to assess the safety and feasibility of NMP in deceased donors with AKI. The primary outcome was DGF. Secondary outcomes were duration of DGF, biopsy-proven rejection, postoperative intrarenal resistive index, postoperative infections, hospital stay duration, primary nonfunction, and kidney function estimated glomerular filtrate rate at discharge, 3 mo, and 1 y. Results: Five pairs of AKI kidneys (NMP versus SCS) were included in the final analysis. The results show no statistically significant differences in clinical outcomes between NMP versus SCS kidneys; however, NMP kidneys demonstrated slightly improved estimated glomerular filtrate rate at 3 mo (59.8 ± 5.93 [59] versus 75.20 ± 14.94 [74]) mL/min/1.73 m2 (P < 0.065) and at the last follow-up (12-29 mo) (72.80 ± 10.71 [75]) versus (94 ± 22.67 [82]) mL/min/1.73 m2 (P < 0.059) as compared with SCS kidneys. A higher proportion of NMP kidneys had normal intrarenal resistive index (0.5-0.7) and mild acute tubular injury on protocol biopsy, suggesting NMP is safe and feasible in deceased donors with acute kidney injury. Conclusions: NMPs of AKI donor kidneys are safe and feasible. A larger cohort is required to explore the reconditioning effect of NMP on AKI kidneys.

Correlation between soluble receptor for advanced glycation end products levels and coronary artery disease in postmenopausal nondiabetic women.

BACKGROUND: The established cardiovascular risk factors cannot explain the overall risk of coronary artery disease (CAD), especially in women. Therefore, there is a growing need for the assessment of novel biomarkers to identify women at risk. The receptor for advanced glycation end products (RAGE) and its interaction with the advanced glycation end product (AGE) ligand have been associated with atherogenesis. The soluble fraction of RAGE (sRAGE) antagonizes RAGE signaling and exerts an antiatherogenic effect. AIM: The study aim was to explore the association between plasma levels of sRAGE and CAD in nondiabetic postmenopausal women. METHODS: This case-control study included 110 nondiabetic postmenopausal women who were enrolled in two groups. Group I included 55 angiographically proven CAD subjects with > 50% stenosis in at least one of the major coronary arteries and Group II included 55 healthy control women who did not have CAD or had < 50% stenosis of the coronary arteries. Stenosis was confirmed by invasive angiography. Plasma sRAGE was determined by an enzyme-linked immunosorbent assay. RESULTS: We observed significantly lower plasma sRAGE concentrations in subjects with CAD vs healthy controls (P < 0.05). Univariate and multivariate logistic regression analysis also revealed a significant correlation between plasma sRAGE levels and CAD (P = 0.01). Multivariate odds ratios for CAD revealed that subjects with sRAGE concentrations below 225 pg/mL (lowest quartile) had a 6-fold increase in CAD prevalence independent of other risk factors. CONCLUSION: Our findings indicated that low sRAGE levels were independently associated with CAD in nondiabetic postmenopausal women. Risk assessment of CAD in postmenopausal women can be improved by including sRAGE along with other risk factors.

Absent circadian rhythm of proteinuria in hospitalized patients with preeclampsia.

OBJECTIVE: To study the variation of protein excretion in short-interval day-and-night collections in hospitalized preeclamptic patients on continuous bed rest. METHODS: We prospectively studied 50 patients admitted to the hospital with the diagnosis of preeclampsia. Urine volumes in 2-, 4-, 12-, and 24-h durations were recorded. Protein concentrations in different volumes of urine were measured. Paired t-test was used to compare the volumes, concentrations, and the total amounts of protein in these samples of different durations. RESULTS: There was no significant difference in the volume of urine and the concentration of proteinuria in the day when compared to night (12-h samples) (p > 0.05). The total amount of protein excreted was comparable for the two durations of samples. For shorter-duration collections (4- and 2-h), the difference in proteinuria between day and night samples remained blunted. CONCLUSION: This study concludes that there is blunting of variation in protein excretion as observed in short-interval urine collections at different times of the day in hypertensive pregnant patients on continuous bed rest.

Effect of Vitamin E on sP-Selectin Levels in Pre-Eclampsia.

P-selectin, a cell adhesion molecule is elevated in many inflammatory conditions including preeclampsia which is characterized by generalized endothelial dysfunction and vasoconstriction presumably due to free radicals or mediators released by defective placentation. Vitamin E has been documented to protect cell membranes from oxidative damage and also decrease platelet aggregation. The role of vitamin E in pre-eclampsia is contradictory and hence the study was undertaken. Soluble P-selectin was measured by ELISA and Vitamin-E levels in plasma was estimated spectrofluorometrically. In our study the effect of supplementation of 400 IU/day of Vitamin E (a-tocopheryl acetate) to patients of pre-eclampsia showed significant decreased levels of soluble P-selectin by 2nd week as compared to patients given placebo (P = 0.005). In this short period of study no direct correlations were observed between Vitamin E or P-selectin levels with blood pressure as well as with proteinuria. Future studies may focus on the effect of a-tocopheryl acetate or the phosphate form of Vitamin-E, recently proposed to be the more active form on other inflammatory markers like IL-6, an important stimuli of P-selectin release in pre-eclampsia.